Scientists have found a way to target elusive cells that suppress immune response, depleting them with peptides that spare other important cells and shrink tumours in preclinical experiments. A [s]News-Medical[/s] quotes lead author, Larry Kwak, director of the [b]Centre for Cancer Immunology Research[/b] at the [b]University of Texas MD Anderson Cancer Centre[/b] as saying: ‘We’ve known about these cells blocking immune response for a decade, but haven't been able to shut them down for lack of an identified target.’ 'The key to taking cancer vaccines to another level is combining them with immunotherapies that target the tumour microenvironment,’ Kwak said.
[link url=http://www.news-medical.net/news/20140526/Peptide-antibodies-hit-immune-response-stifling-MDSCs-without-harming-other-vital-cells.aspx?page=2]Full News-Medical report[/link]
[link url=http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.3560.html]Nature abstract[/link]